BE2016C025I2 - - Google Patents

Download PDF

Info

Publication number: BE2016C025I2
Authority: BE; Belgium
Prior art keywords: diabetic; disease; renal; pharmaceutically acceptable; heart failure
Prior art date: 2002-01-17

Application number

BE2016C025C

Other languages

English (en)

Dutch (nl)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-17

Filing date

2016-05-18

Publication date

2022-05-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23373410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2016C025(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-05-18 Application filed by Novartis Ag filed Critical Novartis Ag

2022-05-17 Publication of BE2016C025I2 publication Critical patent/BE2016C025I2/nl

Links

206010012601 diabetes mellitus Diseases 0.000 abstract 4
206010019280 Heart failures Diseases 0.000 abstract 3
206010002383 Angina Pectoris Diseases 0.000 abstract 2
206010020772 Hypertension Diseases 0.000 abstract 2
208000001647 Renal Insufficiency Diseases 0.000 abstract 2
201000006370 kidney failure Diseases 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
201000001320 Atherosclerosis Diseases 0.000 abstract 1
206010003658 Atrial Fibrillation Diseases 0.000 abstract 1
206010003662 Atrial flutter Diseases 0.000 abstract 1
239000004072 C09CA03 - Valsartan Substances 0.000 abstract 1
206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 abstract 1
208000010412 Glaucoma Diseases 0.000 abstract 1
206010018364 Glomerulonephritis Diseases 0.000 abstract 1
206010049694 Left Ventricular Dysfunction Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
208000019695 Migraine disease Diseases 0.000 abstract 1
208000021642 Muscular disease Diseases 0.000 abstract 1
201000009623 Myopathy Diseases 0.000 abstract 1
208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
206010064911 Pulmonary arterial hypertension Diseases 0.000 abstract 1
208000003782 Raynaud disease Diseases 0.000 abstract 1
208000012322 Raynaud phenomenon Diseases 0.000 abstract 1
206010039710 Scleroderma Diseases 0.000 abstract 1
206010039808 Secondary aldosteronism Diseases 0.000 abstract 1
206010042600 Supraventricular arrhythmias Diseases 0.000 abstract 1
208000032594 Vascular Remodeling Diseases 0.000 abstract 1
206010047281 Ventricular arrhythmia Diseases 0.000 abstract 1
230000001154 acute effect Effects 0.000 abstract 1
239000000400 angiotensin II type 1 receptor blocker Substances 0.000 abstract 1
230000000747 cardiac effect Effects 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
208000010877 cognitive disease Diseases 0.000 abstract 1
230000001627 detrimental effect Effects 0.000 abstract 1
208000033679 diabetic kidney disease Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
206010061989 glomerulosclerosis Diseases 0.000 abstract 1
206010020718 hyperplasia Diseases 0.000 abstract 1
206010020871 hypertrophic cardiomyopathy Diseases 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
208000017169 kidney disease Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
206010027599 migraine Diseases 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
201000008312 primary pulmonary hypertension Diseases 0.000 abstract 1
201000001474 proteinuria Diseases 0.000 abstract 1
208000037812 secondary pulmonary hypertension Diseases 0.000 abstract 1
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 abstract 1
229960004699 valsartan Drugs 0.000 abstract 1
230000002792 vascular Effects 0.000 abstract 1
208000019553 vascular disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BE2016C025C 2002-01-17 2016-05-18 BE2016C025I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34966002P	2002-01-17	2002-01-17
PCT/EP2003/000415 WO2003059345A1 (fr)	2002-01-17	2003-01-16	Compositions pharmaceutiques a base de valsartan et d'inhibiteurs nep

Publications (1)

Publication Number	Publication Date
BE2016C025I2 true BE2016C025I2 (fr)	2022-05-17

Family

ID=23373410

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2016C025C BE2016C025I2 (fr)	2002-01-17	2016-05-18

Country Status (29)

Country	Link
EP (1)	EP1467728B1 (fr)
JP (2)	JP4820056B2 (fr)
KR (2)	KR100984939B1 (fr)
CN (2)	CN1615134A (fr)
AT (1)	ATE370732T1 (fr)
AU (1)	AU2003206738C1 (fr)
BE (1)	BE2016C025I2 (fr)
BR (2)	BR122018015003B8 (fr)
CA (1)	CA2472399C (fr)
CO (1)	CO5600999A2 (fr)
CY (2)	CY1106959T1 (fr)
DE (1)	DE60315795T2 (fr)
DK (1)	DK1467728T3 (fr)
EC (1)	ECSP045190A (fr)
ES (1)	ES2290429T3 (fr)
FR (1)	FR16C0019I2 (fr)
HU (1)	HUS1600024I1 (fr)
IL (2)	IL162661A0 (fr)
LU (1)	LU93074I2 (fr)
MX (1)	MXPA04006917A (fr)
NL (1)	NL300811I2 (fr)
NO (2)	NO333191B1 (fr)
NZ (1)	NZ533968A (fr)
PL (1)	PL212318B1 (fr)
PT (1)	PT1467728E (fr)
RU (1)	RU2334513C3 (fr)
SI (1)	SI1467728T1 (fr)
WO (1)	WO2003059345A1 (fr)
ZA (1)	ZA200405117B (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2384346C2 (ru) *	2004-06-23	2010-03-20	Зольвай Фармасьютиклз Гмбх	Фармацевтические композиции, содержащие nep-ингибиторы, ингибиторы эндогенной эндотелинпродуцирующей системы и антагонисты at1-рецептора
AU2005318365B2 (en) *	2004-12-24	2011-02-03	Krka, D.D., Novo Mesto	Solid pharmaceutical composition comprising valsartan
MY146830A (en) *	2005-02-11	2012-09-28	Novartis Ag	Combination of organic compounds
WO2007045663A2 (fr) *	2005-10-19	2007-04-26	Novartis Ag	Combinaison de composes organiques
WO2007051007A2 (fr) *	2005-10-28	2007-05-03	Novartis Ag	Combinaison de composes organiques
AR057882A1 (es)	2005-11-09	2007-12-26	Novartis Ag	Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007106708A2 (fr) *	2006-03-10	2007-09-20	Novartis Ag	Combinaison de composes organiques
CZ300801B6 (cs) *	2006-06-07	2009-08-12	Helvetia Pharma A.S.	Kompozice s valsartanem v pevných lékových formách
BRPI0806700A8 (pt)	2007-01-12	2019-01-22	Novartis Ag	processo
GB0708507D0 (en)	2007-05-02	2007-06-13	Queen Mary & Westfield College	Substituted phosphonates and their use
ES2536514T3 (es) *	2007-11-06	2015-05-26	Novartis Ag	Composiciones farmacéuticas de doble acción basadas en superestructuras de antagonista/bloqueador de receptores de angiotensina (ARB) y receptor de endopeptidasa neutra (NEP)
CN101774941A (zh)	2009-01-13	2010-07-14	浙江九洲药业股份有限公司	2-酰基氨基-3-联苯基丙酸的制备及拆分方法
CA2763572C (fr)	2009-05-28	2017-10-17	Novartis Ag	Derives aminopropioniques substitues comme inhibiteurs de neprilysine
MA33364B1 (fr)	2009-05-28	2012-06-01	Novartis Ag	Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
JO2967B1 (en)	2009-11-20	2016-03-15	نوفارتس ايه جي	Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
CA2806780A1 (fr)	2010-08-23	2012-03-01	Novartis Ag	Procede de preparation d'intermediaires pour produire des inhibiteurs de l'endopeptidase neutre (epn)
US8673974B2 (en)	2010-11-16	2014-03-18	Novartis Ag	Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
SI2887961T1 (sl) *	2012-08-24	2021-08-31	Novartis Ag	Zaviralci NEP za zdravljenje bolezni, značilnih po atrialni širitvi ali preoblikovanju
WO2014126979A1 (fr)	2013-02-14	2014-08-21	Novartis Ag	Dérivés d'acide phosphonique butanoïque de bisphénol substitués en qualité d'inhibiteurs de nep (endopeptidase neutre)
AU2014216417B2 (en)	2013-02-14	2016-05-12	Novartis Ag	Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy
CN104230865B (zh) *	2013-06-13	2018-01-09	上海翰森生物医药科技有限公司	联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途
JP2016530282A (ja)	2013-08-26	2016-09-29	ノバルティスアーゲー	新規使用
SI4321157T1 (sl) *	2013-08-26	2025-03-31	Novartis Ag	Nova uporaba kombinacije blokatorja receptorja angiotenzina (arb) z nevtralnim zaviralcem endopeptidaze (nepi)
WO2016029828A1 (fr) *	2014-08-27	2016-03-03	上海翰森生物医药科技有限公司	Acide crystallin libre, sel hemicalcique et sel d'alpha-phényléthylamine de ahu-377 et son procédé de préparation et son application
WO2016037098A1 (fr) *	2014-09-04	2016-03-10	Concert Pharmaceuticals, Inc.	Sacubitril deutérisé
WO2016037552A1 (fr) *	2014-09-09	2016-03-17	上海翰森生物医药科技有限公司	Composé cristallin bloqueur de récepteur de l'angiotensine-inhibiteur d'endopeptidase neutre (arb-nepi), son procédé de préparation et son application
CN105503760A (zh) *	2014-10-10	2016-04-20	上海翰森生物医药科技有限公司	结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
PL3218351T3 (pl)	2014-11-14	2019-12-31	Zentiva K.S.	Sposób wytwarzania, wyodrębniania i oczyszczania farmaceutycznie dopuszczalnych postaci AHU-377
CN107074744B (zh) *	2014-12-03	2019-06-18	上海翰森生物医药科技有限公司	Nep抑制剂结晶型游离酸、钙盐多晶型及其制备方法和应用
CN110938042B (zh) *	2014-12-08	2022-12-13	苏州晶云药物科技股份有限公司	一种包含缬沙坦和ahu377的三钠盐超分子复合物的新晶型及其制备方法
CN105693543B (zh) *	2014-12-15	2018-08-10	四川海思科制药有限公司	沙库比曲类衍生物、其药物组合物、制备方法及用途
CN104826115A (zh) *	2015-04-19	2015-08-12	浙江巨泰药业有限公司	一种抗心衰药物组合物及其制备方法
CN106138069A (zh) *	2015-04-21	2016-11-23	刘春丽	作为治疗来自非角化复层上皮组织的不适的局部药剂的1-二仲丁基膦酰基戊烷
RS64242B1 (sr)	2015-05-11	2023-06-30	Novartis Ag	Režim doziranja sakubitril-valsartana za lečenje srčane insuficijencije
EP3302460A1 (fr)	2015-05-29	2018-04-11	Novartis AG	Sacubitril et valsartan pour le traitement d'une maladie métabolique
WO2017006254A1 (fr)	2015-07-08	2017-01-12	Novartis Ag	Combinaison de médicaments comprenant un antagoniste du récepteur de l'angiotensine ii, un inhibiteur d'endopeptidase neutre et un antagoniste du récepteur de minéralocorticoïdes
WO2017012600A1 (fr)	2015-07-20	2017-01-26	Zentiva, K.S.	Composition pharmaceutique contenant du valsartan et du sacubitril et procédés de préparation et de stabilisation correspondants
CN106397248A (zh) *	2015-08-03	2017-02-15	深圳信立泰药业股份有限公司	一种lcz696结晶粉末及其制备方法
US10596151B2 (en)	2015-08-28	2020-03-24	Novartis Ag	Methods and pharmaceutical compositions for reducing arterial stiffness with a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme
WO2017036420A1 (fr) *	2015-09-06	2017-03-09	常州方楠医药技术有限公司	Composition pharmaceutique contenant du valsartan et du sacubitril, et procédé de préparation associé
CN105348209B (zh) *	2015-12-09	2017-12-26	浙江天宇药业股份有限公司	一种抗心衰药lcz696的制备方法
WO2017097275A1 (fr)	2015-12-11	2017-06-15	Zentiva, K.S.	Formes solides d'ester éthylique d'acide (2r,4s)-5-(biphényl-4-yl)-4-[(3-carboxypropionyl)amino]-2-méthylpentanoïque, ses sels et son procédé de préparation
HK1256865A1 (zh)	2016-02-03	2019-10-04	Novartis Ag	有机化合物的盖伦制剂
EP4609912A3 (fr)	2016-02-03	2025-11-12	Novartis AG	Nouvelle utilisation d'une combinaison de sacubitril et de valsartan
EP3524250B1 (fr)	2016-10-08	2025-07-16	Wuhan LL Science And Technology Development Co., Ltd.	Composition pharmaceutique comprenant un inhibiteur de l'endopeptidase neutre (nep) et un dérivé de l'ester d'azilsartan et son utilisation pour le traitement des maladies cardiovasculaires
WO2018211479A1 (fr)	2017-05-19	2018-11-22	Lupin Limited	Compositions stabilisées d'inhibiteurs de l'angiotensine ii et d'inhibiteurs de l'endopeptidase neutre, et leur procédé de préparation
WO2019008485A1 (fr)	2017-07-06	2019-01-10	Mankind Pharma Ltd	Composition pharmaceutique à dose fixe à base de valsartan et de sacubitril
MX391562B (es)	2017-07-28	2025-03-21	Synthon Bv	Composicion farmaceutica que comprende sacubitril y valsartan
UY38072A (es)	2018-02-07	2019-10-01	Novartis Ag	Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
CN110237071B (zh)	2018-03-09	2022-03-22	武汉朗来科技发展有限公司	药物制剂及其应用
KR20210032437A (ko)	2018-08-23	2021-03-24	노파르티스 아게	심부전의 치료를 위한 신규한 약제학적 용도
WO2020039394A1 (fr)	2018-08-24	2020-02-27	Novartis Ag	Nouvelles combinaisons de médicaments
KR20210101164A (ko)	2020-02-07	2021-08-18	보령제약 주식회사	하이브리드 화합물 및 그 제조방법
WO2021158084A1 (fr) *	2020-02-07	2021-08-12	보령제약 주식회사	Composé hybride et son procédé de préparation
KR20200020746A (ko)	2020-02-07	2020-02-26	보령제약 주식회사	하이브리드 화합물 및 그 제조방법
KR20210120560A (ko)	2020-03-27	2021-10-07	주식회사 유영제약	고함량의 주성분을 포함하는 정제 및 그 제조방법
KR20220091767A (ko)	2020-12-24	2022-07-01	주식회사 보령	사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물
EP4640213A1 (fr)	2022-12-20	2025-10-29	THPharm Corp.	Préparation pharmaceutique orale comprenant un inhibiteur du cotransporteur de sodium-glucose de type 2 et un bloqueur du récepteur de l'angiotensine ii
JP2025541480A (ja)	2022-12-20	2025-12-18	ティーエイチファームコーポレーション	ナトリウム－グルコース共輸送体－２阻害剤およびアンジオテンシンｉｉ受容体遮断剤を含む心血管疾患の予防または治療用薬学的組成物
CN116687921A (zh) *	2023-06-14	2023-09-05	宁波大学	沙库巴曲缬沙坦类物质在制备神经毒性和认知障碍类药物的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1256692A (en) *	1991-02-06	1992-09-07	Schering Corporation	Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor
US5217996A (en) *	1992-01-22	1993-06-08	Ciba-Geigy Corporation	Biaryl substituted 4-amino-butyric acid amides
CA2168066A1 (fr) *	1995-02-08	1996-08-09	James R. Powell	Traitement de l'hypertension et de l'insuffisance cardiaque globale
JP2003533440A (ja) *	2000-04-03	2003-11-11	ブリストル−マイヤーズスクイブカンパニー	隔離心収縮期高血圧症を処置するバソペプチダーゼ抑制剤
IL153428A0 (en) *	2000-06-22	2003-07-06	Novartis Ag	Solid valsartan pharmaceutical compositions
IL153882A0 (en) *	2000-07-19	2003-07-31	Novartis Ag	Valsartan salts
US6777443B2 (en) *	2001-05-15	2004-08-17	Novartis Ag	Dipeptide derivatives

2003
- 2003-01-16 EP EP03704413A patent/EP1467728B1/fr not_active Expired - Lifetime
- 2003-01-16 WO PCT/EP2003/000415 patent/WO2003059345A1/fr not_active Ceased
- 2003-01-16 BR BR122018015003A patent/BR122018015003B8/pt not_active IP Right Cessation
- 2003-01-16 DE DE60315795T patent/DE60315795T2/de not_active Expired - Lifetime
- 2003-01-16 JP JP2003559507A patent/JP4820056B2/ja not_active Expired - Lifetime
- 2003-01-16 CA CA2472399A patent/CA2472399C/fr not_active Expired - Lifetime
- 2003-01-16 CN CNA038022680A patent/CN1615134A/zh active Pending
- 2003-01-16 KR KR1020047011124A patent/KR100984939B1/ko not_active Ceased
- 2003-01-16 CN CN201110029600.7A patent/CN102091330B/zh not_active Expired - Lifetime
- 2003-01-16 AT AT03704413T patent/ATE370732T1/de active
- 2003-01-16 PT PT03704413T patent/PT1467728E/pt unknown
- 2003-01-16 NZ NZ533968A patent/NZ533968A/en not_active IP Right Cessation
- 2003-01-16 DK DK03704413T patent/DK1467728T3/da active
- 2003-01-16 BR BRPI0306907A patent/BRPI0306907B8/pt active IP Right Grant
- 2003-01-16 ES ES03704413T patent/ES2290429T3/es not_active Expired - Lifetime
- 2003-01-16 KR KR1020107010521A patent/KR20100057704A/ko not_active Ceased
- 2003-01-16 IL IL16266103A patent/IL162661A0/xx unknown
- 2003-01-16 PL PL369773A patent/PL212318B1/pl unknown
- 2003-01-16 MX MXPA04006917A patent/MXPA04006917A/es active IP Right Grant
- 2003-01-16 AU AU2003206738A patent/AU2003206738C1/en active Active
- 2003-01-16 RU RU2004125178A patent/RU2334513C3/ru active
- 2003-01-16 SI SI200331029T patent/SI1467728T1/sl unknown
2004
- 2004-06-21 IL IL162661A patent/IL162661A/en active Protection Beyond IP Right Term
- 2004-06-28 ZA ZA2004/05117A patent/ZA200405117B/en unknown
- 2004-07-14 EC EC2004005190A patent/ECSP045190A/es unknown
- 2004-08-06 CO CO04076723A patent/CO5600999A2/es active IP Right Grant
- 2004-08-13 NO NO20043380A patent/NO333191B1/no not_active IP Right Cessation
2007
- 2007-10-25 CY CY20071101386T patent/CY1106959T1/el unknown
2011
- 2011-05-25 JP JP2011116928A patent/JP2011207898A/ja not_active Withdrawn
2016
- 2016-05-17 FR FR16C0019C patent/FR16C0019I2/fr active Active
- 2016-05-18 NL NL300811C patent/NL300811I2/nl unknown
- 2016-05-18 CY CY2016013C patent/CY2016013I1/el unknown
- 2016-05-18 NO NO2016009C patent/NO2016009I1/no unknown
- 2016-05-18 HU HUS1600024C patent/HUS1600024I1/hu unknown
- 2016-05-18 LU LU93074C patent/LU93074I2/fr unknown
- 2016-05-18 BE BE2016C025C patent/BE2016C025I2/nl unknown

Also Published As

Publication number	Publication date
CN1615134A (zh)	2005-05-11
NO2016009I2 (no)	2016-05-18
CN102091330B (zh)	2015-04-08
EP1467728B1 (fr)	2007-08-22
CA2472399A1 (fr)	2003-07-24
KR100984939B9 (ko)	2024-07-17
NO2016009I1 (no)	2016-05-18
ATE370732T1 (de)	2007-09-15
FR16C0019I1 (fr)	2016-06-24
IL162661A (en)	2010-11-30
PT1467728E (pt)	2007-11-14
RU2334513C3 (ru)	2017-10-24
FR16C0019I2 (fr)	2017-12-08
PL212318B1 (pl)	2012-09-28
AU2003206738C1 (en)	2020-01-30
LU93074I2 (fr)	2016-07-18
CY1106959T1 (el)	2012-01-25
CY2016013I2 (el)	2016-10-05
BR122018015003B1 (pt)	2018-11-21
NO20043380L (no)	2004-10-07
BR0306907A (pt)	2004-12-21
RU2334513C2 (ru)	2008-09-27
AU2003206738A1 (en)	2003-07-30
JP2011207898A (ja)	2011-10-20
DK1467728T3 (da)	2007-12-27
AU2003206738B2 (en)	2006-12-21
NO333191B1 (no)	2013-03-25
HUS1600024I1 (hu)	2016-06-28
PL369773A1 (en)	2005-05-02
IL162661A0 (en)	2005-11-20
KR20040078127A (ko)	2004-09-08
EP1467728A1 (fr)	2004-10-20
JP2005514441A (ja)	2005-05-19
JP4820056B2 (ja)	2011-11-24
KR100984939B1 (ko)	2010-10-01
ES2290429T3 (es)	2008-02-16
ZA200405117B (en)	2005-08-31
NZ533968A (en)	2006-10-27
RU2004125178A (ru)	2005-06-10
ECSP045190A (es)	2004-08-27
MXPA04006917A (es)	2004-12-06
NL300811I2 (fr)	2016-07-27
SI1467728T1 (sl)	2008-02-29
CO5600999A2 (es)	2006-01-31
CY2016013I1 (el)	2016-10-05
DE60315795T2 (de)	2008-06-05
DE60315795D1 (de)	2007-10-04
BR122018015003B8 (pt)	2021-07-27
KR20100057704A (ko)	2010-05-31
CA2472399C (fr)	2012-02-21
WO2003059345A1 (fr)	2003-07-24
CN102091330A (zh)	2011-06-15
BRPI0306907B1 (pt)	2018-10-30
BRPI0306907B8 (pt)	2021-05-25

Publication	Publication Date	Title
NL300811I2 (fr)	2016-07-27
WO2007106708A3 (fr)	2007-12-27	Combinaison de composes organiques
EP2322174A3 (fr)	2011-07-27	Utilisation combinée de valsartane et bloqueurs du canal de calcium à but thérapeutique
EP1507558B8 (fr)	2012-02-15	Composition pharmaceutique comprenant un inhibiteur de renine, un agent de blocage du canal du calcium et un diuretique
BR0317384A (pt)	2005-11-16	Combinações de valsartan com inibidores de cox-2